A detailed history of Strs Ohio transactions in Immunovant, Inc. stock. As of the latest transaction made, Strs Ohio holds 4,000 shares of IMVT stock, worth $110,040. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,000
Previous 17,500 77.14%
Holding current value
$110,040
Previous $462,000 76.19%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

SELL
$27.51 - $27.51 $371,385 - $371,385
-13,500 Reduced 77.14%
4,000 $110,000
Q2 2024

Aug 05, 2024

BUY
$25.1 - $31.61 $45,180 - $56,898
1,800 Added 11.46%
17,500 $462,000
Q1 2024

May 13, 2024

SELL
$30.27 - $43.79 $75,675 - $109,475
-2,500 Reduced 13.74%
15,700 $507,000
Q4 2023

Jan 30, 2024

SELL
$31.31 - $44.19 $485,305 - $684,945
-15,500 Reduced 45.99%
18,200 $766,000
Q3 2023

Oct 26, 2023

SELL
$18.55 - $39.96 $44,520 - $95,904
-2,400 Reduced 6.65%
33,700 $1.29 Million
Q2 2023

Jul 31, 2023

SELL
$14.2 - $23.75 $24,140 - $40,375
-1,700 Reduced 4.5%
36,100 $684,000
Q1 2023

Aug 02, 2023

BUY
$15.27 - $19.72 $25,959 - $33,524
1,700 Added 4.71%
37,800 $586,000
Q1 2023

Apr 27, 2023

BUY
$15.27 - $19.72 $27,486 - $35,496
1,800 Added 5.0%
37,800 $586,000
Q4 2022

Jan 26, 2023

BUY
$6.59 - $17.75 $58,651 - $157,975
8,900 Added 32.84%
36,000 $639,000
Q4 2021

Jan 24, 2022

BUY
$7.33 - $9.32 $138,537 - $176,148
18,900 Added 230.49%
27,100 $230,000
Q3 2021

Oct 22, 2021

BUY
$7.01 - $11.37 $57,482 - $93,234
8,200 New
8,200 $71,000
Q1 2021

Apr 23, 2021

SELL
$13.08 - $49.6 $119,028 - $451,360
-9,100 Closed
0 $0
Q4 2020

Jan 25, 2021

BUY
$36.36 - $52.71 $14,544 - $21,084
400 Added 4.6%
9,100 $420,000
Q3 2020

Dec 14, 2020

BUY
$22.61 - $38.9 $85,918 - $147,820
3,800 Added 77.55%
8,700 $306,000
Q2 2020

Jul 23, 2020

BUY
$13.87 - $28.44 $67,963 - $139,356
4,900 New
4,900 $119,000

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Strs Ohio Portfolio

Follow Strs Ohio and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Strs Ohio, based on Form 13F filings with the SEC.

News

Stay updated on Strs Ohio with notifications on news.